Dialysate, also known as dialysis solution, dialysis fluid, or bath, is a solution containing purified water, electrolytes, and salts as such sodium bicarbonate. The goal of dialysate is to pull toxins from the circulation into the dialysate. This is performed by the diffusion process. Dialysate is classified into 2.5m Eq/L, 3.5m Eq/L, and others based on its composition.
Market Drivers and Forecast
According to OMR Research, the global dialysate market is projected to grow at a CAGR of 5.7% during the forecast period (2023–2029). Dialysate market expansion is being driven by an increase in the prevalence of chronic kidney disorders, which is increasing patient visits to renal treatment clinics. According to 2021 estimates from the Centers for Disease Control and Prevention, 37 million US individuals, or more than 1 in 7, were suffering from chronic renal disease in that year. Moreover, as kidney diseases are more common among older individuals, the growth of the aging population will also affect the market’s growth significantly. According to World Health Organization (WHO) projections, one in every six people on the planet will be 60 or older by 2030, and the number of people aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. Additionally, by 2050, the world's population of adults aged 60 and up will have doubled (to 2.1 billion).
Another factor contributing to the market’s growth is the prevalence of diabetes. According to the International Diabetes Federation, 537 million adults were living with diabetes in 2021, which amounts to 1 in every 10 individuals. These numbers are further anticipated to rise by 2030 and reach 643 million, and by 2045, 783 million. According to the WHO, diabetes and diabetes-related kidney disease caused an estimated 2 million deaths in 2019. The reason behind the use of dialysate in diabetes is that the disease causes damage to the body's tiny blood vessels. The patient's organs are unable to clear their blood effectively if the blood vessels in the kidneys are harmed. Diabetes patients who also have end-stage renal disease have an even greater problem. Diabetes patients must have greater urea clearance rates than other patients in order to have a better chance of survival. This may be challenging with multisystem organ participation. Hence, dialysis is required for them to do this.
Furthermore, the market is expected to rise as a result of COVID-19. Individuals suffering from COVID-19 face renal disorders since critically ill individuals experience multiple organ failure, including kidney failure. According to the National Institutes of Health (NIH), around 5% of COVID-19 patients have acute kidney damage and require renal replacement treatment.
Recent Developments
The key companies in the global dialysate market include Fresenius Medical Care AG & Co. KGaA, Baxter, Diality, Inc., Fresenius Medical Care AG & Co. KGaA , Guangdong Biolight Meditech, Informa PLC, M Dialysis AB, NxStage Medical, Inc., and Weigao Group, among others. These companies are following various mergers, collaborations, new product launches, and other development activities for the market’s growth, such as-
• In February 2023, Rockwell Medical, Inc., a commercial healthcare company dedicated to providing life-sustaining products for patients with severe blood disorders and renal disease, announced a three-year product purchase contract with Concerto Renal Services ("Concerto"), the provider of dialysis in skilled nursing centers. Under the terms of the agreement, Rockwell Medical will be Concerto's main provider of liquid and dry acid and bicarbonate concentrates for three years, with supply and purchase minimums.
• In September 2022, Terumo Corporation announced that the National Medical Products Administration (NMPA) has granted regulatory approval to WEGO Terumo (Weihai) Medical Products CO., Ltd. (WEGO Terumo), a joint project of medical device manufacturer WEGO and Terumo, to manufacture and market a neutral peritoneal dialysis solution. This product is planned to be available in China in early 2023 and will be the first neutralized peritoneal dialysis solution.